Petzinger GM - Search Results

1

A naturally occurring variant of SHLP2 is a protective factor in Parkinson's disease.

Kim SJ, Miller B, Hartel NG, Ramirez R 2nd, Braniff RG, Leelaprachakul N, Huang A, Wang Y, Arpawong TE, Crimmins EM, Wang P, Sun X, Liu C, Levy D, Yen K, Petzinger GM, Graham NA, Jakowec MW, Cohen P. Kim SJ, et al. Among authors: petzinger gm. Mol Psychiatry. 2024 Feb;29(2):505-517. doi: 10.1038/s41380-023-02344-0. Epub 2024 Jan 3. Mol Psychiatry. 2024. PMID: 38167865 Free PMC article.

2

Fentanyl-induced dyskinesias.

Petzinger G, Mayer SA, Przedborski S. Petzinger G, et al. Mov Disord. 1995 Sep;10(5):679-80. doi: 10.1002/mds.870100526. Mov Disord. 1995. PMID: 8552126 No abstract available.

3

A case of tetrabenazine-induced neuroleptic malignant syndrome after prolonged treatment.

Petzinger GM, Bressman SB. Petzinger GM, et al. Mov Disord. 1997 Mar;12(2):246-8. doi: 10.1002/mds.870120219. Mov Disord. 1997. PMID: 9087987 No abstract available.

4

Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1.

Elm JJ; NINDS NET-PD Investigators. Elm JJ, et al. Mov Disord. 2012 Oct;27(12):1513-21. doi: 10.1002/mds.25175. Mov Disord. 2012. PMID: 23079770 Free PMC article. Clinical Trial.

5

Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson's disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER.

LeWitt PA, Boroojerdi B, Surmann E, Poewe W; SP716 Study Group; SP715 Study Group. LeWitt PA, et al. J Neural Transm (Vienna). 2013 Jul;120(7):1069-81. doi: 10.1007/s00702-012-0925-5. Epub 2012 Dec 4. J Neural Transm (Vienna). 2013. PMID: 23208198 Free PMC article. Clinical Trial.

6

A kinder, gentler dopamine… highlighting dopamine's role in behavioral flexibility.

Beeler JA, Cools R, Luciana M, Ostlund SB, Petzinger G. Beeler JA, et al. Front Neurosci. 2014 Jan 24;8:4. doi: 10.3389/fnins.2014.00004. eCollection 2014. Front Neurosci. 2014. PMID: 24478624 Free PMC article. No abstract available.

7

Complete ascertainment of Parkinson disease in the Swedish Twin Registry.

Wirdefeldt K, Gatz M, Bakaysa SL, Fiske A, Flensburg M, Petzinger GM, Widner H, Lew MF, Welsh M, Pedersen NL. Wirdefeldt K, et al. Among authors: petzinger gm. Neurobiol Aging. 2008 Dec;29(12):1765-73. doi: 10.1016/j.neurobiolaging.2007.04.009. Epub 2007 May 29. Neurobiol Aging. 2008. PMID: 17532098 Free PMC article.

8

The native form of alpha-synuclein is not found in the cerebrospinal fluid of patients with Parkinson's disease or normal controls.

Jakowec MW, Petzinger GM, Sastry S, Donaldson DM, McCormack A, Langston JW. Jakowec MW, et al. Among authors: petzinger gm. Neurosci Lett. 1998 Aug 28;253(1):13-6. doi: 10.1016/s0304-3940(98)00599-0. Neurosci Lett. 1998. PMID: 9754793

9

Experimental models of Parkinson's disease: insights from many models.

Tolwani RJ, Jakowec MW, Petzinger GM, Green S, Waggie K. Tolwani RJ, et al. Among authors: petzinger gm. Lab Anim Sci. 1999 Aug;49(4):363-71. Lab Anim Sci. 1999. PMID: 10480640 Review.

10

Investigating levodopa-induced dyskinesias in the parkinsonian primate.

Langston JW, Quik M, Petzinger G, Jakowec M, Di Monte DA. Langston JW, et al. Ann Neurol. 2000 Apr;47(4 Suppl 1):S79-89. Ann Neurol. 2000. PMID: 10762135 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

72 results

Search Page